

ISO 17099:2024-06 (E)

Radiological protection - Performance criteria for laboratories using the cytokinesis-block micronucleus (CBMN) assay in peripheral blood lymphocytes for biological dosimetry

Contents		Page
	Foreword.....	v
	Introduction.....	vii
1	Scope	1
2	Normative references	1
3	Terms and definitions	1
4	CMBN assay methodology used in this document	3
	4.1 General.....	3
	4.2 Requests for analysis and blood sampling.....	3
5	Responsibility of the requestor	3
6	Responsibility of the service laboratory	4
	6.1 Setup and sustainment of the quality assurance program.....	4
	6.2 Responsibility during service.....	4
7	Confidentiality of personal information	5
	7.1 Overview.....	5
	7.2 Applications of the principle of confidentiality.....	5
	7.2.1 Delegation of responsibilities within the laboratory.....	5
	7.2.2 Requests for analysis.....	6
	7.2.3 Transmission of confidential information.....	6
	7.2.4 Anonymity of samples.....	6
	7.2.5 Reporting of results.....	6
	7.2.6 Storage.....	6
	7.2.7 Data security plan.....	6
8	Laboratory safety requirements	6
	8.1 Overview.....	6
	8.2 Microbiological safety requirements.....	7
	8.3 Chemical safety requirements.....	7
	8.4 Optical safety requirements.....	8
	8.5 Safety plan.....	8
9	Sample processing	8
	9.1 Culturing.....	8
	9.2 Staining.....	10
	9.3 Microscopy.....	10
	9.4 Scoring of slides.....	10
	9.4.1 General.....	10
	9.4.2 Criteria for scoring.....	10
	9.4.3 Scoring data sheets.....	11
	9.5 Automated analysis.....	11
10	Calibration source(s), calibration curve, and minimum detectable dose	11
	10.1 Calibration source(s).....	11
	10.2 Calibration curve.....	11
	10.3 Background MN frequency.....	12
	10.4 Comparison with the background level: Characterisation of the minimum detectable dose.....	13
11	Accidental exposure involving few individuals	15

11.1	Procedure for scoring MN in BNCs	15
11.1.1	Coding of samples and slides	15
11.1.2	Scoring techniques	16
11.1.3	Laboratory scoring expertise	16
11.2	Criteria for converting a MN yield into an estimate of absorbed dose	16
11.2.1	Overview	16
11.2.2	Comparison with controls	16
11.2.3	Confidence limits on the number of MN	16
11.2.4	Calculation of absorbed dose for whole-body exposures	16
11.2.5	Calculation of uncertainty on absorbed dose	17
11.2.6	Acute and non-acute exposure cases	17
11.2.7	Testing the distribution of MN per BNC	18
11.2.8	Other exposure scenarios	18
11.3	Reporting of results	18
11.3.1	General	18
11.3.2	Content of the report (see Annex D for a standard form)	18
11.3.3	Interpretation of the results	19
12	Population triage	19
12.1	General	19
12.2	Use of a CBMN assay network for large scale exposures	19
12.3	Procedure for scoring MN in BNCs	20
12.4	Criteria for converting a MN yield into an estimate of absorbed dose	20
12.5	Reporting of results	20
13	Quality assurance and quality control	20
13.1	Overview	20
13.2	Specific requirement	20
13.2.1	General	20
13.2.2	Performance checks by laboratory inter-comparisons	20
13.2.3	Periodical performance check of scorer qualification	21
13.2.4	Performance checks of sample transport integrity	21
13.2.5	Performance checks of sample integrity by service laboratory	21
13.2.6	Performance checks for instrumentation	21
13.2.7	Performance checks of sample protocol	22
13.2.8	Performance checks of sample scoring	22
13.2.9	Performance checks of dose and confidence limits estimation	22
13.2.10	Performance checks for result report generation	22
	Annex A (informative) Sample data sheet for recording MN in BNCs	23
	Annex B (informative) Instructions for requestor (sample)	24
	Annex C (informative) Sample questionnaire	25
	Annex D (informative) Sample of report for single assessment	27
	Annex E (informative) Sample group report	29
	Annex F (informative) Decision threshold and detection limit	31
	Bibliography	34